Jump to Main Contents
国立がん研究センター 中央病院

Home > ATLAS Project Research Members

ATLAS Project Research Members

National Cancer Center Hospital (Tokyo, Japan)

SHIMOI Tatsunori (Department of Clinical Oncology)


SHIMOI Tatsunori MD, PhD

Dr. SHIMOI's story

I have a strong background in translational breast cancer research in the areas of molecular targeted therapeutics and genomic medicine. In graduate school, I have researched association between genomic abnormalities in breast cancer tissues, and their clinical behavior or their responsibleness to treatment. I have also been seconded to the Ministry of Health, Labour and Welfare (MHLW), and based on this experience, I have been giving my opinions from a professional perspective as a member of the MHLW's Council, as well as making policy recommendations regarding Japan's healthcare administration. I also have a strong interest in clinical research on rare cancers, including soft tissue sarcomas, germ cell tumors and so on. Currently, I am an active physician with experience in conducting clinical trials of both molecularly targeted therapeutics and immunotherapy.

Research interests

I have experience working for a government agency, so I am interested in policy recommendations for medical policy. I am particularly interested in medical economics, cancer genome medical policy, and palliative medicine.
As for cancer genome medicine, I have obtained public research funding as a primary investigator and am running a clinical trial.As for translational research, I am interested in genomic abnormalities in cancer and predictors of response to immunotherapy in breast cancer and soft tissue sarcoma.
Japan is an island nation with a single language, so our culture has not been predisposed to accepting patients from other countries. However, in response to the trend toward internationalization, I believe it will be my mission to enhance international medical care at the hospital in order to promote more research.

Professional Experiences

  • 2020-current Head of Physician, Department of Medical Oncology, National Cancer Center Hospital.
  • 2017-2019 Ministry of Health, Labour and Welfare
  • 2013-2020 Clinical Fellowship and Staff Physician, Department of Medical Oncology, National Cancer Center Hospital.
  • 2007-2013 Clinical Residency, and Clinical Fellowship, Internal Medicine and Medical Oncology, Cancer and Infectious disease center Komagome Hospital.
  • 2001-2007 Gifu University School of Medicine

Selected publications

  1. Hotspot mutation profiles of AKT1 in Asian women with breast and endometrial cancers. Shimoi T, Hashimoto J, Sudo K, Shimomura A, Noguchi E, Shimizu C, Yunokawa M, Yonemori K, Yoshida H, Yoshida M, Kato T, Kinoshita T, Fukuda T, Fujiwara Y, Tamura K. BMC Cancer. 2021 Oct 21;21(1):1131.
  2. Critical Appraisal of Adjuvant Platinum-Based Chemotherapy for Basal Subtype Triple-Negative Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy. Shimoi T, Noguchi E, Sudo K, Chua YJ, Yonemori K. J Clin Oncol. 2021 Nov 1;39(31):3519-3521.
  3. Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study. Kitadai R, Shimoi T, Sudo K, Noguchi E, Nagata Y, Sawada R, Takashima A, Boku N, Yonemori K. BMC Cancer. 2021 Mar 20;21(1):294
  4. Neoadjuvant Cisplatin in BRCA Carriers With HER2-Negative Breast Cancer. Takamizawa S, Ishiki H, Shimoi T, Shimizu M, Satomi E. J Clin Oncol. 2020 Aug 10;38(23):2699-2700.
  5. The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition. Shimoi T, Nagai SE, Yoshinami T, Takahashi M, Arioka H, Ishihara M, Kikawa Y, Koizumi K, Kondo N, Sagara Y, Takada M, Takano T, Tsurutani J, Naito Y, Nakamura R, Hattori M, Hara F, Hayashi N, Mizuno T, Miyashita M, Yamashita N, Yamanaka T, Saji S, Iwata H, Toyama T. Breast Cancer. 2020 May;27(3):322-331.
  6. First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis. Shimoi T, Sagara Y, Hara F, Toyama T, Iwata H.
    Breast Cancer. 2020 May;27(3):340-346.
  7. Bone marrow examination in patients with Ewing sarcoma/peripheral primitive neuroectodermal tumor without metastasis based on 18F-fluorodeoxyglucose positron emission tomography/computed tomography. Inagaki C, Shimoi T, Sumiyoshi Okuma H, Kawachi A, Sudo K, Shimomura A, Noguchi E, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Arakawa A, Ogawa C, Yoshida A, Fujiwara Y, Tamura K. Med Oncol. 2019 May 18;36(7):58.
  8. The Incidence of Nonmalignant Diseases among Patients with Suspected Carcinoma of Unknown Primary Site. Sato J, Shimoi T, Shimomura A, Noguchi E, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Yoshida M, Tamura K. Intern Med. 2019 May 15;58(10):1423-1428.
  9. PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system. Shimoi T, Hamada A, Yamagishi M, Hirai M, Yoshida M, Nishikawa T, Sudo K, Shimomura A, Noguchi E, Yunokawa M, Yonemori K, Shimizu C, Kinoshita T, Fukuda T, Fujiwara Y, Tamura K. Cancer Sci. 2018 Aug;109(8):2558-2566.
  10. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, Shimizu C, Shimoi T, Kuboki Y, Matsubara N, Kitano A, Jikoh T, Lee C, Fujisaki Y, Ogitani Y, Yver A, Tamura K. Lancet Oncol. 2017 Nov;18(11):1512-1522.